Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Placebo-controlled, Double-blind, Two-part Study to Evaluate the Safety and Tolerability of NGM395 in Adult Obese Patients (Part 1) and in Adult Patients With Nonalcoholic Fatty Liver Disease (NAFLD) (Part 2)

Next Previous
Trial Profile

A Phase 1, Randomized, Placebo-controlled, Double-blind, Two-part Study to Evaluate the Safety and Tolerability of NGM395 in Adult Obese Patients (Part 1) and in Adult Patients With Nonalcoholic Fatty Liver Disease (NAFLD) (Part 2)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NGM 395 (Primary)
  • Indications Non-alcoholic fatty liver disease; Obesity
  • Focus Adverse reactions
  • Sponsors NGM Biopharmaceuticals

Most Recent Events

  • 19 Jul 2021 Status changed from recruiting to completed.
  • 17 Mar 2020 According to a NGM Biopharmaceuticals media release, NGM dosed the first patient in the Phase 1 single ascending dose clinical study in obese but otherwise healthy adults (Part 1).
  • 17 Mar 2020 Status changed from not yet recruiting to recruiting, according to a NGM Biopharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top